glulisine insulin, glargine insulin — Competitive Intelligence Brief

glulisine insulin, glargine insulin (glulisine insulin, glargine insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: insulin analog. Area: Diabetes.

phase 3 insulin analog insulin receptor Diabetes Small molecule

Target snapshot

glulisine insulin, glargine insulin (glulisine insulin, glargine insulin) — Population Health Research Institute. Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
glulisine insulin, glargine insulin TARGET	glulisine insulin, glargine insulin	Population Health Research Institute	phase 3	insulin analog	insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (insulin analog class)

1. Biodel · 1 drug in this class
2. Population Health Research Institute · 1 drug in this class
3. Sanofi · 1 drug in this class